Physician profile
Ingrid Wecht
NPI 1619074234
$1,990.34
in general payments reported to CMS, 2019-2025
25 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $363 · 2021: $323 · 2022: $247 · 2023: $413 · 2024: $133 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $675 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $675.18 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $371.03 | 2019-2025 | Veozah |
| Abbvie INC. | $294.29 | 2019-2024 | Lo Loestrin Fe |
| Pfizer INC. | $202.30 | 2019-2023 | |
| Organon LLC | $189.58 | 2021-2025 | Nexplanon |
| Therapeuticsmd, INC. | $114.06 | 2019-2022 | |
| Hologic Sales and Service, LLC | $104.14 | 2019-2025 | Myosure Tissue Removal Device, Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $96.05 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $80.50 | 2021-2025 | |
| Amgen INC. | $66.76 | 2021-2023 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $65.26 | 2020-2021 | |
| Exeltis, USA INC. | $58.67 | 2022-2023 | Slynd |
| Novo Nordisk INC | $50.89 | 2025 | Wegovy |
| Sage Therapeutics, LLC | $38.62 | 2022-2023 | |
| Mylan Pharmaceuticals INC. | $37.07 | 2020-2021 | |
| Agile Therapeutics, INC. | $30.59 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $27.45 | 2020 | |
| Avion Pharmaceuticals | $26.59 | 2019-2021 | |
| Medicem INC. | $23.86 | 2023 | |
| Sumitomo Pharma America, INC. | $22.59 | 2024 | Myfembree |
| Urovant Sciences INC | $22.07 | 2022 | |
| Coopersurgical, INC. | $14.41 | 2020 | |
| Mission Pharmacal Company | $14.00 | 2019 | |
| Currax Pharmaceuticals LLC | $13.93 | 2025 | Contrave, Onzetra Xsail |
| Amag Pharmaceuticals, INC. | $13.92 | 2019 | |
| Meditrina | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrid Wecht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.